Expert review of neurotherapeutics
-
With the advent of modern neuroimaging techniques, transient ischemic attack (TIA) has been redefined as, "a transient episode of neurological dysfunction caused by focal brain, spinal cord or retinal ischemia, without acute infarction." If infarct is evident on neuroimaging, the event is a stroke. It is important to recognize and correctly diagnose TIA and minor stroke because of the substantial early risk of stroke. Much of the early stroke risk is attributable to large artery atherosclerosis. ⋯ There is, however, abundant data to support inclusion of neuroimaging in stroke-risk determination, which can also be combined with a clinical risk assessment. The hybrid ABCDE⊕ score further refines early stroke risk. Rapid assessment and treatment in the emergency department or in specially designed 'TIA clinics' appear to reduce stroke rate.
-
Expert Rev Neurother · Feb 2013
ReviewCommonly asked questions in the management of perioperative stroke.
Certain surgical interventions increase stroke risk. Perioperative stroke significantly increases perioperative morbidity and mortality. Several interventions, such as perioperative continuation of antithrombotic therapy during selected surgical interventions, may decrease stroke risk without significantly increasing rates of adverse effects. Commonly asked questions in the management of perioperative stroke includes: What are the mechanisms of perioperative stroke? What are the stroke risk factors and perioperative risks? What is the perioperative stroke risk with discontinuation of antithrombotic medications? What risk modifications strategies can be implemented to decrease perioperative stroke risk? What is the role of neuroimaging in the management of perioperative stroke? What is the evidence for the management of perioperative acute ischemic stroke? This article provide an evidence-based review to these questions and comments on potential interventions in the management of these patients.
-
Expert Rev Neurother · Feb 2013
ReviewEndocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
Spasticity is a disabling complication of multiple sclerosis. Some commonly used oral medications include baclofen, tizanidine, anticonvulsants and benzodiazepines, but their benefits are modest. Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain) is a unique cannabinoid-based medicine with two main active ingredients; 9-δ-tetrahydrocannabinol, which acts mainly on cannabinoid 1 receptors in the CNS and plays a key role in the modulation of spasticity and spasms, and cannabidiol, which has different properties, including minimization of the psychoactivity associated with 9-δ-tetrahydrocannabinol. ⋯ Interim data from the UK as well as Spanish Sativex safety registries confirm that clinical benefit is maintained over the longer term despite the expected trend for deterioration owing to disease progression. Even after more than 2 years of use, no new safety/tolerability signals have emerged with Sativex, including no evidence of driving impairment and no relevant incidence of falls or other adverse events of concern, such as psychiatric or nervous system events. Sativex appears to be a well-tolerated and useful add-on therapy in patients who have not achieved an adequate response with traditional antispastic agents.
-
Expert Rev Neurother · Feb 2013
ReviewUse of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues.
Currently, intravenous thrombolysis is by far the most effective treatment of acute ischemic stroke, and its use can independently strongly increase the proportion of stroke patients surviving. While the use of recombinant tissue plasminogen activator in accordance to licensed criteria has continuously risen, off-label use is also frequent. In this review the most important reasons to transcend current license criteria are discussed and evidence is summarized from new studies, such as IST-3, contributing to the balance of increased benefit as opposed to possible harm in situations of off-label use of recombinant tissue plasminogen activator in stroke. In addition, several scores to predict risk and outcome in patients undergoing thrombolysis are compared.
-
Expert Rev Neurother · Feb 2013
ReviewA new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain), a cannabinoid oromucosal spray containing a 1:1 ratio of 9-δ-tetrahydrocannabinol and cannabidiol, has been licensed in Germany since July 2011 as add-on therapy for moderate-to-severe multiple sclerosis (MS) treatment-resistant spasticity symptoms. The 'MOVE 2' study evaluated clinical outcomes, treatment satisfaction, quality of life (QoL) and provision of care in MS patients with spasticity receiving Sativex in everyday clinical practice. Data from 300 patients were collected from 42 specialized MS centers across Germany and were available for this analysis. ⋯ Sativex was generally well tolerated. The majority of patients (84%) reported no adverse events, and there was only a limited risk of serious adverse reactions. Furthermore, based on data from Sativex clinical trials, a Markov model-based analysis has shown that Sativex is a cost-effective treatment option for patients with MS spasticity in Germany.